BioLine RxFRA:YP2 -2.36%21 Days Inventory is 2,033.89 as of Mar. 2026, which is 953% above its 10-year median of 193.08. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, BioLine Rx ranks worse than 96.24% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). BioLine Rx's Average Total Inventories for the
three
months ended in Mar. 2026 was €1.85 Mil. BioLine Rx's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €0.08 Mil.
Hence, BioLine Rx's Days Inventory for the
three
months ended in Mar. 2026 was 2,033.89.
The historical rank and industry rank for BioLine Rx's Days Inventory or its related term are showing as below:
FRA:YP2'
s Days Inventory Range Over the Past 10 Years
Min: 100.44 Med: 193.08 Max: 4202.3
Current: 3174.28
During the past 13 years, BioLine Rx's highest Days Inventory was 4202.30. The lowest was 100.44. And the median was 193.08.
FRA:YP2's Days Inventory is ranked worse than 96.24% of 638
companies
in the Biotechnology industry
Industry Median: 183.875
vs FRA:YP2: 3174.28
BioLine Rx's Days Inventory
declined
from Mar. 2025 (8,653.07) to Mar. 2026 (2,033.89).
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioLine Rx's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.04.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioLine Rx's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 4.48.
BioLine Rx (FRA:YP2) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
BioLine Rx's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioLine Rx's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
BioLine Rx Days Inventory Related Terms
BioLine Rx Days Inventory Historical Data
* Premium members only.
The historical data trend for BioLine Rx's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:YP2 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, BioLine Rx's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLine Rx Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLine Rx's Days Inventory distribution charts can be found below:
* The bar in red indicates where BioLine Rx's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLine Rx (FRA:YP2) has a Days Inventory of 2,033.89 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioLine Rx and its competitors. This is 953% above median its historical median of 193.08. Over the past decade, BioLine Rx's Days Inventory has ranged from 100.44 to 4,202.30. According to the industry distribution chart, BioLine Rx ranks #614 out of 638 companies in the Biotechnology industry, placing it in the top 96.2%.
Is BioLine Rx's Days Inventory too high?
BioLine Rx's current Days Inventory of 2,033.89 is 953% above median its 10-year median of 193.08. Over the past 10 years, this metric has ranged from a low of 100.44 to a high of 4,202.30. The Biotechnology industry median Days Inventory is 183.88. BioLine Rx's value of 2,033.89 is 1006.1% above this industry median. Based on the distribution chart, BioLine Rx ranks #614 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLine Rx ranks #614 out of 638 companies for Days Inventory. This places BioLine Rx in the lower half of its industry. The industry median Days Inventory is 183.88. BioLine Rx's value of 2,033.89 is 1006.1% above this benchmark. Historically, BioLine Rx's own Days Inventory has ranged from 100.44 to 4,202.30 over the past decade. While the company's 10-year median is 193.08 vs. the industry median of 183.88, BioLine Rx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLine Rx's current Days Inventory of 2,033.89 is 1006.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioLine Rx and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLine Rx's current Days Inventory is 2,033.89, which is 953% above median its own 10-year median of 193.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current Days Inventory of 2,033.89. The current Days Inventory is 2,033.89, which is 953% above median its 10-year median of 193.08 and 1006.1% above the Biotechnology industry median of 183.88. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Days Inventory is 2,033.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score
Get the complete analysis for FRA:YP2
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:YP2 has been successfully added to your 
